1 Llc Alphaeon Net Worth

The estimated Net Worth of 1 Llc Alphaeon is at least $105 Milion dollars as of 17 February 2023. 1 Alphaeon owns over 1,850,000 units of Evolus Inc stock worth over $64,361,080 and over the last 3 years 1 sold EOLS stock worth over $40,216,013.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

1 Alphaeon EOLS stock SEC Form 4 insiders trading

1 has made over 2 trades of the Evolus Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently 1 sold 1,850,000 units of EOLS stock worth $15,540,000 on 17 February 2023.

The largest trade 1's ever made was selling 2,597,475 units of Evolus Inc stock on 2 September 2021 worth over $24,676,013. On average, 1 trades about 2,223,738 units every 267 days since 2021. As of 17 February 2023 1 still owns at least 4,214,871 units of Evolus Inc stock.

You can see the complete history of 1 Alphaeon stock trades at the bottom of the page.

What's 1 Alphaeon's mailing address?

1's mailing address filed with the SEC is 4040 MACARTHUR BOULEVARD, SUITE 310, , NEWPORT BEACH, CA, 92660.

Insiders trading at Evolus Inc

Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox a 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.

What does Evolus Inc do?

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.

Complete history of 1 Alphaeon stock trades at Evolus Inc

Evolus Inc executives and stock owners

Evolus Inc executives and other stock owners filed with the SEC include:

• Michael Jafar,
  Chief Commercial Officer
• David Moatazedi,
  President, Chief Executive Officer, Director
• Rui Avelar,
  Chief Medical Officer, Head of Research & Development
• David Moatazedi,
  Pres, CEO & Director
• Lauren Silvernail,
  Chief Financial Officer, Executive Vice President - Corporate Development
• Lauren P. Silvernail,
  CFO & Exec. VP of Corp. Devel.
• Dr. Rui Avelar Dip.SportMed, M.D., C.CFP,
  Chief Medical Officer and Head of R&D
• Karah Parschauer,
  Independent Director
• Peter Farrell,
  Independent Director
• Vikram Malik,
  Chairman of the Board
• David Gill,
  Independent Director
• Robert Hayman,
  Independent Director
• Simone Blank,
  Director
• Tram Bui,
  IR Contact Officer
• Jeff Plumer,
  General Counsel
• Jessica Novak,
  Sr. VP of HR
• Crystal Muilenburg,
  Chief Marketing Officer
• Kurt Knab,
  VP of Sales
• Jeffrey J. Plumer,
  Gen. Counsel
• David K. Erickson,
  VP of Investor Relations
• Biopharma, Inc. Aeon,
  
• Sandra Beaver,
  Chief Financial Officer
• Crystal Muilenburg,
  Chief Marketing Officer
• Albert G Iii White,
  Director
• Kristine Romine,
  Director
• Bosun Hau,
  Director
• 1 Llc Alphaeon,
  
• Brady Stewart,
  Director
• Tomoko Yamagishi Dressler,
  Chief Marketing Officer
• Inc. Medytox,